Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., explained in plain language.
-
New Dual-Action antibody enters first human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called SIM0689 in adults with advanced solid tumors that have stopped responding to standard treatments. SIM0689 is a bispecific antibody designed to block two cancer-promoting pathways (PD1 and VEGF). The trial will first find a safe dose,…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Not yet recruitingThis study tests a new injectable drug called SIM0278 for adults with moderate to severe atopic dermatitis (eczema) that needs systemic treatment. About 184 participants will receive either a low, medium, or high dose of SIM0278 or a placebo. The main goal is to see how much ecze…
Phase: PHASE2 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC